STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer

El Ahanidi,Hajar; El Azzouzi,Meryem; Addoum,Boutaina; Tetou,Mohammed; Hassan,Ilyass; Al Bouzidi,Abderrahmane; Oukabli,Mohammed; Hafidi Alaoui,Chaimae; Chaoui,Imane; Benbacer,Laila; El Mzibri,Mohammed; Ameur,Ahmed; Jandus,Camilla; Attaleb,Mohammed

doi:10.3892/mco.2025.2828

STAT1 and STAT4 expression as prognostic biomarkers in patients with bladder cancer

Authors:
- Hajar El Ahanidi
- Meryem El Azzouzi
- Boutaina Addoum
- Mohammed Tetou
- Ilyass Hassan
- Abderrahmane Al Bouzidi
- Mohammed Oukabli
- Chaimae Hafidi Alaoui
- Imane Chaoui
- Laila Benbacer
- Mohammed El Mzibri
- Ahmed Ameur
- Camilla Jandus
- Mohammed Attaleb
View Affiliations

Affiliations: Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, CH‑1211 Geneva 4, Switzerland, Biology and Medical Research Unit, National Center for Energy, Nuclear Sciences and Techniques, 10010 Rabat, Morocco, Urology Department, Military Hospital of Rabat, 10000 Rabat, Morocco, Pathology Department, Military Hospital of Rabat, 10000 Rabat, Morocco
Published online on: February 6, 2025 https://doi.org/10.3892/mco.2025.2828
Article Number: 33
Copyright: © El Ahanidi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Signal transducer and activator of transcription (STAT) proteins are cytoplasmic transcription factors known to play key roles in numerous physiological and pathological processes, from pathogen response to cancer modulation. However, the roles of some STAT family members, particularly STAT1 and STAT4, in the initiation and progression of bladder cancer (BC) have not been comprehensively studied. The present study investigated the expression pattern of STAT1 and STAT4 in the prognosis and survival of BC taking advantage of patients' specimens and cell lines. In our cohort, high mRNA expression of STAT1 was significantly associated with tumor invasiveness, recurrence and progression, and was shown to increase according to tumor stage in BC cell lines. However, it did not affect patient survival. By contrast, STAT4 exhibited its highest expression in early‑stage tumors, without a significant link to the tumor stage. Moreover, it was found that increased STAT4 mRNA expression was associated with improved disease‑free survival and overall survival in our cohort. Collectively, these findings suggest that STAT1 and STAT4 could be promising prognostic markers to enhance BC management.

View Figures

View References

1	Liu Q: Current advances in N6-methyladenosine methylation modification during bladder cancer. Front Genet. 12(825109)2022.PubMed/NCBI View Article : Google Scholar
2	Inamura K: Bladder cancer: New insights into its molecular pathology. Cancers (Basel). 10(100)2018.PubMed/NCBI View Article : Google Scholar
3	Becerra-Díaz M, Valderrama-Carvajal H and Terrazas LI: Signal transducers and activators of transcription (STAT) family members in helminth infections. Int J Biol Sci. 7:1371–1381. 2011.PubMed/NCBI View Article : Google Scholar
4	Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, et al: The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 60:41–56. 2020.PubMed/NCBI View Article : Google Scholar
5	Alunno A, Padjen I, Fanouriakis A and Boumpas DT: Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: Integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells. 8(898)2019.PubMed/NCBI View Article : Google Scholar
6	Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, Takahashi N and Taketomi A: Interleukin-6/STAT 3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci. 108:1947–1952. 2017.PubMed/NCBI View Article : Google Scholar
7	Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, Loy A, Huang V, Cheng G and Lin J: Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer. 7(78)2008.PubMed/NCBI View Article : Google Scholar
8	Meissl K, Macho-Maschler S, Müller M and Strobl B: The good and the bad faces of STAT1 in solid tumours. Cytokine. 89:12–20. 2017.PubMed/NCBI View Article : Google Scholar
9	Pensa sara, Regis G, Boselli D, Novelli F and Poli V: STAT1 and STAT3 in tumorigenesis: Two sides of the same coin? In: Madame Curie Bioscience Database. Landes Bioscience, Austin, TX, 2013.
10	Wubetu GY, Utsunomiya T, Ishikawa D, Yamada S, Ikemoto T, Morine Y, Iwahashi S, Saito Y, Arakawa Y and Imura S: , et al: High STAT4 expression is a better prognostic indicator in patients with hepatocellular carcinoma After Hepatectomy. Ann Surg Oncol. 21 (Suppl 4):S721–S728. 2014.PubMed/NCBI View Article : Google Scholar
11	Zhou X, Xia Y, Su J and Zhang G: Down-regulation of miR-141 induced by helicobacter pylori promotes the invasion of gastric cancer by targeting STAT4. Cell Physiol Biochem. 33:1003–1012. 2014.PubMed/NCBI View Article : Google Scholar
12	Cheng JM, Yao MR, Zhu Q, Wu XY, Zhou J, Tan WL and Zhan SH: Silencing of stat4 gene inhibits cell proliferation and invasion of colorectal cancer cells. J Biol Regul Homeost Agents. 29:85–92. 2015.PubMed/NCBI
13	Zhao L, Ji G, Le X, Luo Z, Wang C, Feng M, Xu L, Zhang Y, Lau WB, Lau B, et al: An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis. Oncogene. 36:3384–3396. 2017.PubMed/NCBI View Article : Google Scholar
14	Anderson K, Ryan N, Volpedo G, Varikuti S, Satoskar AR and Oghumu S: Immune suppression mediated by STAT4 deficiency promotes lymphatic metastasis in HNSCC. Front Immunol. 10(3095)2020.PubMed/NCBI View Article : Google Scholar
15	Hedl M, Sun R and Abraham C: Disease risk-associated genetic variants in STAT1 and STAT4 function in a complementary manner to increase pattern-recognition receptor-induced outcomes in human macrophages. J Immunol. 205:1406–1418. 2020.PubMed/NCBI View Article : Google Scholar
16	Vanoni G, Ercolano G, Candiani S, Rutigliani M, Lanata M, Derré L, Marcenaro E, Schneider P, Romero P, Jandus C and Trabanelli S: Human primed ILCPs support endothelial activation through NF-κB signaling. ELife. 10(e58838)2021.PubMed/NCBI View Article : Google Scholar
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
18	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
19	El Ahanidi H, El Azzouzi M, Hafidi Alaoui C, Tetou M, Bensaid M, Chaoui I, Benbacer L, Hassan I, Oukabli M, Michaud K, et al: Immune checkpoint and telomerase crosstalk is mediated by miRNA-138 in bladder cancer. Front Oncol. 11(795242)2022.PubMed/NCBI View Article : Google Scholar
20	El Azzouzi M, El Ahanidi H, Hassan I, Tetou M, Ameur A, Bensaid M, Al Bouzidi A, Oukabli M, Alaoui CH, Addoum B, et al: Comprehensive behavioural assessment of TERT in bladder cancer. Urol Oncol. 42:451.e19–451.e29. 2024.PubMed/NCBI View Article : Google Scholar
21	Zhang Q: STAT1 as a potential therapeutic target to treat bladder cancer. Int J Clin Exp Pathol. 17:298–307. 2024.PubMed/NCBI View Article : Google Scholar
22	Gao B, Li X, Li S, Wang S, Wu J and Li J: Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker. Phenomics. 2:33–49. 2022.PubMed/NCBI View Article : Google Scholar
23	Hashmi AA, Hussain ZF, Irfan M, Khan EY, Faridi N, Naqvi H, Khan A and Edhi MM: Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder. BMC Urol. 18(59)2018.PubMed/NCBI View Article : Google Scholar
24	Hu Y, Dong Z and Liu K: Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res. 43(23)2024.PubMed/NCBI View Article : Google Scholar
25	Zhang C, Xu X, Wang T, Lu Y, Lu Z, Wang T and Pan Z: Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder. Sci Rep. 14(7941)2024.PubMed/NCBI View Article : Google Scholar
26	Zhang J, Wang F, Liu F and Xu G: Predicting STAT1 as a prognostic marker in patients with solid cancer. Ther Adv Med Oncol. 12(1758835920917558)2020.PubMed/NCBI View Article : Google Scholar
27	Yang C, Mai H, Peng J, Zhou B, Hou J and Jiang D: STAT4: an immunoregulator contributing to diverse human diseases. Int J Biol Sci. 16:1575–1585. 2020.PubMed/NCBI View Article : Google Scholar
28	Litvinov IV, Cordeiro B, Fredholm S, Ødum N, Zargham H, Huang Y, Zhou Y, Pehr K, Kupper TS, Woetmann A and Sasseville D: Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines. Cell Cycle. 13:2975–2982. 2014.PubMed/NCBI View Article : Google Scholar
29	Zhou M, Zhang P, Da M, Yang R, Ma Y, Zhao J, Ma T, Xia J, Shen G, Chen Y and Chen D: A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment. Front Oncol. 12(925537)2022.PubMed/NCBI View Article : Google Scholar
30	Li C, Zhao J, Kang B, Li S, Tang J, Dong D and Chen Y: Identification and validation of STAT4 as a prognostic biomarker in acute myeloid leukemia. Biosci Rep. 44(BSR20231720)2024.PubMed/NCBI View Article : Google Scholar